Loading...
•
Sep 30, 2022
Allogene Q3 2022 Earnings Report
Allogene Therapeutics reported financial results for the third quarter of 2022 and announced an Investor R&D Showcase.
Key Takeaways
Allogene Therapeutics reported the initiation of their Phase 2 ALPHA2 trial and ended the third quarter with $637 million in cash, cash equivalents and investments. The company will host a Research & Development Showcase on November 29, 2022.
Initiated the Industry’s First Allogeneic CAR T Phase 2 Trial (ALPHA2 Trial).
Readiness activities underway for initiation of the EXPAND Trial.
Company to Host Research & Development Showcase on November 29, 2022.
Ended Third Quarter with $637 Million in Cash, Cash Equivalents and Investments.
Forward Guidance
The Company expects full year GAAP Operating Expenses to be slightly below the low end of its prior guidance of $360 million and $390 million, including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. Cash burn for 2022 is expected to be less than $250 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...